Severe bronchiectasis is associated with increased carotid intima-media thickness.
Humans
Bronchiectasis
/ diagnostic imaging
Male
Female
Carotid Intima-Media Thickness
Middle Aged
Prospective Studies
Severity of Illness Index
Hong Kong
/ epidemiology
Carotid Artery Diseases
/ diagnostic imaging
Case-Control Studies
Aged
Predictive Value of Tests
Adult
Risk Factors
Risk Assessment
Bronchiectasis
Cardiovascular disease
Carotid initial thickness
Subclinical atherosclerosis
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
28 Aug 2024
28 Aug 2024
Historique:
received:
12
10
2023
accepted:
19
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
28
8
2024
Statut:
epublish
Résumé
Although bronchiectasis has been shown to be associated with cardiovascular disease, there is limited evidence of an association with subclinical atherosclerosis, especially carotid intima-media thickness (CIMT). This prospective study compared CIMT among patients with and without bronchiectasis, and among bronchiectatic patients classified according to disease severity using the FACED score. The study was carried out at a major regional hospital and tertiary respiratory referral centre in Hong Kong. Total 155 Chinese patients with non-cystic fibrosis (CF) bronchiectasis and 512 controls were recruited. The mean CIMT was 0.58 ± 0.10 mm, 0.63 ± 0.11 mm and 0.66 ± 0.08 mm respectively among controls, patients with mild-to-moderate bronchiectasis and patients with severe bronchiectasis. There was no statistically significant difference in CIMT between patients with mild-to-moderate bronchiectasis and controls. Multivariate linear regression revealed that CIMT was significantly increased in patients with severe bronchiectasis relative to controls. The same phenomenon was observed among patients without a history of cardiovascular disease or cardiovascular risk factors. CIMT was significantly increased in patients with severe bronchiectasis compared with controls without bronchiectasis, but not among patients with mild-to-moderate bronchiectasis, which suggested the subclinical atherosclerosis to be more prevalent among patients with severe bronchiectasis.
Sections du résumé
BACKGROUND
BACKGROUND
Although bronchiectasis has been shown to be associated with cardiovascular disease, there is limited evidence of an association with subclinical atherosclerosis, especially carotid intima-media thickness (CIMT).
METHODS
METHODS
This prospective study compared CIMT among patients with and without bronchiectasis, and among bronchiectatic patients classified according to disease severity using the FACED score. The study was carried out at a major regional hospital and tertiary respiratory referral centre in Hong Kong.
RESULTS
RESULTS
Total 155 Chinese patients with non-cystic fibrosis (CF) bronchiectasis and 512 controls were recruited. The mean CIMT was 0.58 ± 0.10 mm, 0.63 ± 0.11 mm and 0.66 ± 0.08 mm respectively among controls, patients with mild-to-moderate bronchiectasis and patients with severe bronchiectasis. There was no statistically significant difference in CIMT between patients with mild-to-moderate bronchiectasis and controls. Multivariate linear regression revealed that CIMT was significantly increased in patients with severe bronchiectasis relative to controls. The same phenomenon was observed among patients without a history of cardiovascular disease or cardiovascular risk factors.
CONCLUSIONS
CONCLUSIONS
CIMT was significantly increased in patients with severe bronchiectasis compared with controls without bronchiectasis, but not among patients with mild-to-moderate bronchiectasis, which suggested the subclinical atherosclerosis to be more prevalent among patients with severe bronchiectasis.
Identifiants
pubmed: 39198746
doi: 10.1186/s12872-024-04129-x
pii: 10.1186/s12872-024-04129-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
457Informations de copyright
© 2024. The Author(s).
Références
Boyton RJ, Altmann DM. Bronchiectasis: current concepts in Pathogenesis, Immunology, and Microbiology. Annu Rev Pathol. 2016;11:523–54.
pubmed: 26980162
doi: 10.1146/annurev-pathol-012615-044344
Koenig W, Sund M, Frohlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring trends and determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237–42.
pubmed: 9892589
doi: 10.1161/01.CIR.99.2.237
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731–3.
pubmed: 9727541
doi: 10.1161/01.CIR.98.8.731
Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97(20):2007–11.
pubmed: 9610529
doi: 10.1161/01.CIR.97.20.2007
Force USPST, Curry SJ, Krist AH, et al. Risk Assessment for Cardiovascular Disease with nontraditional risk factors: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(3):272–80.
doi: 10.1001/jama.2018.8359
Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol. 2009;25(10):567–79.
pubmed: 19812802
pmcid: 2782500
doi: 10.1016/S0828-282X(09)70715-9
Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.
pubmed: 12551878
doi: 10.1161/01.CIR.0000052939.59093.45
Collaboration IRGCERF, Sarwar N, Butterworth AS, et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012;379(9822):1205–13.
doi: 10.1016/S0140-6736(11)61931-4
Interleukin-6 Receptor Mendelian Randomisation, Analysis C, Swerdlow DI, Holmes MV, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379(9822):1214–24.
doi: 10.1016/S0140-6736(12)60110-X
Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349(17):1595–604.
pubmed: 14573731
doi: 10.1056/NEJMoa035003
Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286(17):2136–42.
pubmed: 11694155
doi: 10.1001/jama.286.17.2136
Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114(4):529–41.
pubmed: 15314690
pmcid: 503769
doi: 10.1172/JCI200421109
Karakas M, Koenig W, Zierer A, et al. Myeloperoxidase is associated with incident coronary heart disease independently of traditional risk factors: results from the MONICA/KORA Augsburg study. J Intern Med. 2012;271(1):43–50.
pubmed: 21535251
doi: 10.1111/j.1365-2796.2011.02397.x
Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104(12):1336–42.
pubmed: 11560847
doi: 10.1161/hc3701.095949
Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002;106(1):24–30.
pubmed: 12093765
doi: 10.1161/01.CIR.0000020546.30940.92
Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111(5):570–5.
pubmed: 15699277
doi: 10.1161/01.CIR.0000154553.12214.CD
Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103(4):491–5.
pubmed: 11157711
doi: 10.1161/01.CIR.103.4.491
Roldan V, Marin F, Lip GY, Blann AD. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost. 2003;90(6):1007–20.
pubmed: 14652631
doi: 10.1160/TH02-09-0083
Tiret L, Godefroy T, Lubos E, et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005;112(5):643–50.
pubmed: 16043644
doi: 10.1161/CIRCULATIONAHA.104.519702
Valgimigli M, Ceconi C, Malagutti P, et al. Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study. Circulation. 2005;111(7):863–70.
pubmed: 15699251
doi: 10.1161/01.CIR.0000155614.35441.69
Saleh AD, Kwok B, Brown JS, Hurst JR. Correlates and assessment of excess cardiovascular risk in bronchiectasis. Eur Respir J 2017;50(5).
Navaratnam V, Millett ER, Hurst JR, et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax. 2017;72(2):161–6.
pubmed: 27573451
doi: 10.1136/thoraxjnl-2015-208188
Mendez R, Feced L, Alcaraz-Serrano V, et al. Cardiovascular events during and after bronchiectasis exacerbations and long-term mortality. Chest. 2022;161(3):629–36.
pubmed: 34656526
doi: 10.1016/j.chest.2021.10.013
Huang JT, Kuzmanova E, Dicker AJ, et al. Serum desmosine is Associated with Long-Term all-cause and Cardiovascular Mortality in Bronchiectasis. Am J Respir Crit Care Med. 2020;202(6):897–9.
pubmed: 32402210
doi: 10.1164/rccm.202002-0434LE
Navaratnam V, Root AA, Douglas I, Smeeth L, Hubbard RB, Quint JK. Cardiovascular outcomes after a respiratory tract infection among adults with non-cystic fibrosis bronchiectasis: a General Population-based study. Ann Am Thorac Soc. 2018;15(3):315–21.
pubmed: 29266966
pmcid: 5880522
doi: 10.1513/AnnalsATS.201706-488OC
Choi H, Kim SH, Han K, et al. Association between exercise and risk of cardiovascular diseases in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2022;23(1):288.
pubmed: 36258193
pmcid: 9580142
doi: 10.1186/s12931-022-02202-7
Gao YH, Liu SX, Cui JJ, et al. Subclinical atherosclerosis in adults with steady-state bronchiectasis: a case-control study. Respir Med. 2018;134:110–6.
pubmed: 29413496
doi: 10.1016/j.rmed.2017.11.024
Costa JC, Machado JN, Ferreira C, Gama J, Rodrigues C. The Bronchiectasis Severity Index and FACED score for assessment of the severity of bronchiectasis. Pulmonology. 2018.
Lau KK, Chan YH, Wong YK, et al. Garlic intake is an independent predictor of endothelial function in patients with ischemic stroke. J Nutr Health Aging. 2013;17(7):600–4.
pubmed: 23933870
doi: 10.1007/s12603-013-0043-6
Lau KK, Chan YH, Yiu KH, et al. Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. J Hum Hypertens. 2007;21(6):445–51.
pubmed: 17361211
doi: 10.1038/sj.jhh.1002178
Touboul PJ, Hennerici MG, Meairs S et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290–296.
Molinari F, Meiburger KM, Saba L, et al. Ultrasound IMT measurement on a multi-ethnic and multi-institutional database: our review and experience using four fully automated and one semi-automated methods. Comput Methods Programs Biomed. 2012;108(3):946–60.
pubmed: 22658832
doi: 10.1016/j.cmpb.2012.05.008
Molinari F, Meiburger KM, Saba L et al. Automated carotid IMT measurement and its validation in low contrast ultrasound database of 885 patient Indian population epidemiological study: results of AtheroEdge
Saba L, Montisci R, Famiglietti L, et al. Automated analysis of intima-media thickness: analysis and performance of CARES 3.0. J Ultrasound Med. 2013;32(7):1127–35.
pubmed: 23804335
doi: 10.7863/ultra.32.7.1127
Naqvi T. Ultrasound vascular screening for cardiovascular risk assessment. Why, when and how? Minerva Cardioangiol. 2006;54(1):53–67.
pubmed: 16467742
van den Munckhof ICL, Jones H, Hopman MTE, et al. Relation between age and carotid artery intima-medial thickness: a systematic review. Clin Cardiol. 2018;41(5):698–704.
pubmed: 29752816
pmcid: 6489962
doi: 10.1002/clc.22934
Kuswardhani RT, Wiradharma KG, Kandarini Y, Widiana GR, Martadiani ED. Factors associated with carotid intima-media thickness in patients on maintenance hemodialysis. Int J Gen Med. 2019;12:1–6.
pubmed: 30588063
doi: 10.2147/IJGM.S178276
Ma M, Wang L, Zhong X, et al. Age and gender differences between carotid intima-media thickness and serum uric acid. Am J Cardiol. 2022;172:137–43.
pubmed: 35317928
doi: 10.1016/j.amjcard.2022.02.023
Chang CC, Chang ML, Huang CH, Chou PC, Ong ET, Chin CH. Carotid intima-media thickness and plaque occurrence in predicting stable angiographic coronary artery disease. Clin Interv Aging. 2013;8:1283–8.
pubmed: 24098074
pmcid: 3789839
Loboz-Rudnicka M, Jaroch J, Bociaga Z, et al. Impact of cardiovascular risk factors on carotid intima-media thickness: sex differences. Clin Interv Aging. 2016;11:721–31.
pubmed: 27307718
pmcid: 4887056
Targonska-Stepniak B, Drelich-Zbroja A, Majdan M. The relationship between carotid intima-media thickness and the activity of rheumatoid arthritis. J Clin Rheumatol. 2011;17(5):249–55.
pubmed: 21778898
doi: 10.1097/RHU.0b013e3182290dbf
Medeiros PBS, Salomao RG, Teixeira SR, et al. Disease activity index is associated with subclinical atherosclerosis in childhood-onset systemic lupus erythematosus. Pediatr Rheumatol Online J. 2021;19(1):35.
pubmed: 33743717
pmcid: 7981852
doi: 10.1186/s12969-021-00513-5
Eder L, Jayakar J, Shanmugarajah S, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2013;72(5):715–20.
pubmed: 22736087
doi: 10.1136/annrheumdis-2012-201497
Van Gestel YR, Flu W-J, van Kuijk J-P, et al. Association of COPD with carotid wall intima-media thickness in vascular surgery patients. Respir Med. 2010;104(5):712–6.
pubmed: 19942421
doi: 10.1016/j.rmed.2009.10.027
Gulbas G, Turan O, Sarioglu N, et al. Carotid intima-media thickness in chronic obstructive pulmonary disease and survival: a multicenter prospective study. Clin Respir J. 2019;13(6):391–9.
pubmed: 30942958
doi: 10.1111/crj.13024
Yılmaz M, Bozkurt Yılmaz HE, Şen N, Altın C, Tekin A, Müderrisoğlu H. Investigation of the relationship between asthma and subclinical atherosclerosis by carotid/femoral intima media and epicardial fat thickness measurement. J Asthma. 2018;55(1):50–6.
pubmed: 28453377
doi: 10.1080/02770903.2017.1313272
Onufrak S, Abramson J, Vaccarino V. Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study. Atherosclerosis. 2007;195(1):129–37.
pubmed: 17045272
doi: 10.1016/j.atherosclerosis.2006.09.004
Tsai C-L, Delclos GL, Huang JS, Hanania NA, Camargo CA Jr. Age-related differences in asthma outcomes in the United States, 1988–2006. Ann Allergy Asthma Immunol. 2013;110(4):240–6. e241.
pubmed: 23535086
doi: 10.1016/j.anai.2013.01.002
Enright PL, Kronmal RA, Higgins MW, Schenker MB, Haponik EF. Prevalence and correlates of respiratory symptoms and disease in the elderly. Chest. 1994;106(3):827–34.
pubmed: 8082366
doi: 10.1378/chest.106.3.827
Nowak JK, Wykrętowicz A, Mądry E, et al. Preclinical atherosclerosis in cystic fibrosis: two distinct presentations are related to pancreatic status. J Cyst Fibros. 2022;21(1):26–33.
pubmed: 34253491
doi: 10.1016/j.jcf.2021.06.010
Gao YH, Cui JJ, Wang LY, et al. Arterial stiffness in adults with steady-state bronchiectasis: association with clinical indices and disease severity. Respir Res. 2018;19(1):86.
pubmed: 29743118
pmcid: 5944117
doi: 10.1186/s12931-018-0790-3
Kelly C, Chalmers JD, Crossingham I et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Reviews 2018(3).
Kwok WC, Tam TCC, Lam DCL, Ip MSM, Ho JCM. Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis. Clin Respir J 2023.
Martínez-García MÁ, Oscullo G, García-Ortega A, Matera MG, Rogliani P, Cazzola M. Inhaled corticosteroids in adults with non-cystic fibrosis bronchiectasis: from bench to Bedside. A narrative review. Drugs. 2022;82(14):1453–68.
pubmed: 36264441
pmcid: 9626424
doi: 10.1007/s40265-022-01785-1